RVX managementHi nextblockbuster.
On your Jan 18th post on Agora you stated "I often wonder if we had a change of management in terms of new fresh leader with pharma experience how much faster a deal would get done and how the investor public would now see a great investment. I have rarely been critical of management but now i am feeling very frustrated with the pace of shareholder value. Tell me again why we needed to hire a vp of investor relations ??? "
I have posted such thoughts as well in the past. Don obviously must have very good relationships with KD/Eastern, NGN and Hepalink and they are the people that keep this little ship afloat. Over my corporate years I've seen many replacements brought into companies thinking they would be "the big solution" and I've watched the failures in many businesses.
I've been very frustrated by Don's flippant attitude, poor presentation qualities and the lack of commitment re timelines and business professionalism. Don does not really need to care... for a number of reasons which I won't mention because I've stated them before. Don't get me wrong. I sense that Don is a really good guy and that he cares passionately for success for him and all of the RVX team. (that was evident on the Zenith side with the restructuring into Zenith Capital and Zenith Epigenetics - which has not yet happened) That's my opinion. On the other hand I feel he has no interest in retail shareholders at all and in fact I even get the sense they he views us with distain. The update of Zenith on Monday in terms of the detail and quality of the presentation and if he addresses the questions many of us have submitted will be an indication of wether he just sees this as a duty OR if he is genuinely proud of the achievements to date.
Having Don in place will also help with Eastern renewing the credit line in 2017 and I have no doubt they will. There is no way they are going to interfer with the scientific progress at that stage and unless they are working behind the scenes with NGN and Hepalink it they can't really take over everything.
At the end of the day this is a science company and Don has little effect on value except every time he presents it does not help the share price. I believe his "brand credibility" is very low.
If/when there is a new regional deal emerging the rumours will drive up the share price and investors will take profit. I have no knowledge but I'm willing to bet it will happen. This will be another key move in Don's chess game because it will further balance power and continue to move RVX into being a downstream producer and marketer. Perhaps this is one of Don's key assets.
One of the drawbacks (perhaps of being leading edge in epigenetics) is that the scientific community has not embraced it. It appears there are no successes to date. Hence, if any one of the Zenith or RVX trials are breakthroughs this is when the $ floodgates will open but we all know this a long way off for both companies.
Don makes promises and often doesn't deliever (Zenith IPO Q4 2015) but that is understandable. He should not make promises. The science team on the other hand is moving forward steadily.
In terms of the VP IR he is from the oil industry as I recall and may take a year to learn this business OR it could also be that Don has something up his sleeve.
Anyway currently and for the forseable future we have excellent buying opportunities.
I remain long and extremely excited by the science. This is cutting edge but yet to be proven.
I posted this on SH because Agora does not like critical analysis.
GLTA
Cheers
Toinv